FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
Topic
Breast Cancer
9 articles on Breast Cancer, written for patients and carers arranging specialty treatment.
-
-
First-Line Palbociclib Combination Boosts PFS in HR+/HER2+ mBC – PATINA Findings
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 1, 2026. n Metastatic breast cancer (mBC) remains
-
Atirmociclib and Fulvestrant Together Delay Cancer Progression in HR+/HER2– Cases
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 23, 2026. Advancements in breast cancer treatment continue
-
Healing After Radiation: Is a Nipple-Sparing Mastectomy Possible?
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 20, 2026. n For many years, patients who
-
Oral SERDs Explained: The New Hormone Therapy Option After Endocrine Resistance in HR+ Breast Cancer
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 25, 2026. n Hormone receptor-positive, HER2-negative breast cancer
-
Does Ribociclib Still Help After 3 Years? The NATALEE Trial’s 4-Year Follow-Up Answers
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 21, 2026. n For patients with hormone receptor–positive,
-
New CDK4/6 Strategies in HR+/HER2– Breast Cancer: Imlunestrant ± Abemaciclib and the Avutometinib Triplet
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 20, 2026. n Hormone receptor–positive, HER2-negative (HR+/HER2–) metastatic
-
Can Men Get Breast Cancer? Symptoms and Causes
Most people think of breast cancer as something that only affects women, but it’s important to know that men can
-
HER2 Status in Breast Cancer: Understanding Positive, Negative, and Low Types
Breast cancer comes in many forms—it’s not the same for everyone. The disease varies a lot based on biology and
Still have a question?
We reply to every enquiry within one working day.